hC Bioscience Announces Lead Program in Hemophilia and Reports Positive Preclinical Data on Novel Protein Editing Approach Using Anticodon Engineered tRNA
Tuesday, 23 April 2024 ()
BOSTON--(BUSINESS WIRE)--hC Bioscience announces lead program in severe hemophilia A and shares preclinical data demonstrating proof-of-concept for tRNA-based protein editing.
|
||||
You Might Like |
||||
